A Deep Pipeline of XmAb Antibody Drug Candidates

XmAb antibodies and cytokines are being developed by Xencor and our partners in more than 20 different clinical programs for the treatment of life-threatening and debilitating diseases.

Our four primary XmAb Fc domains are designed to improve therapeutic antibody performance by enhancing immune regulation, cytotoxic potency, or circulating half-life or by creating bispecific antibody structures that are stable, long-acting and readily produced. The plug-and-play nature of each domain has enabled the rapid discovery of a portfolio of differentiated drug candidates with a diversity of mechanisms, targets and potential disease indications. This clinical portfolio diversity, all from a common basis in Fc domain design, creates a breadth of opportunities for Xencor.